Chemours vs Olin
Olin is the larger business, with $6.78bn of revenue in fiscal 2025 against $5.81bn for Chemours (1.2 times as much). Olin grew faster (3.7% against 0.4%). Olin kept more of each dollar of sales as profit: a net margin of -1.5% against -6.6%.
| Latest fiscal year | ChemoursCC, 2025 | OlinOLN, 2025 |
|---|---|---|
| Revenue | $5.81bn | $6.78bn |
| Revenue growth | 0.4% | 3.7% |
| Net income | −$386m | −$101m |
| Operating margin | — | 0.1% |
| Net margin | -6.6% | -1.5% |
| Return on equity | -94.0% | -5.2% |
| Free cash flow | $51.0m | $248m |
| Cash | $670m | $168m |
| Total debt | $4.18bn | $2.83bn |
| Debt to equity | — | 153.7% |
| Dividend per share | $0.51 | — |
| Dividend yield | 2.7% | 4.4% |
| Share buybacks | — | $50.5m |
| Employees | 5,700 | 7,676 |
| Market value | $1.98bn | $2.07bn |
| Price vs our value range | — | Below our value range |
| Moat score | 46 (Moderate) | 42 (Weak) |
| Insider trades, 12 months | 7 buys, 0 sales | 0 buys, 5 sales |